Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference being held in Boston, MA, from September 8 - 10, 2026.

Wells Fargo 21st Annual Healthcare Conference Details

Format: One-on-one Meetings

Date: September 8 - 10, 2026

If you are interested in arranging a 1×1 meeting with management at the conference, please contact your Wells Fargo representative.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Investor Contact:

Brian Ritchie

LifeSci Advisors

britchie@lifesciadvisors.com

Media Inquiries:

Corporate Communications

media@relmada.com